Daiichi Sankyo Plays Long Game With Quizartinib Outside Japan
Executive Summary
Japanese company Daiichi Sankyo has its eye on first-line FLT3-ITD AML indication after rejection of relapsed/refractory plans in EU and US.
You may also be interested in...
Daiichi Eyes First-Line AML Filings For Vanflyta On Positive Data
Daiichi Sankyo is aiming to overcome past US and EU setbacks for its FLT3 inhibitor Vanflyta with planned filings for first-line AML on the back of positive new Phase III data.
NICE Draft Guidance: Rejects Keytruda In Head & Neck Cancer, Xospata In AML
A series of decisions on anticancer drugs from the UK’s NICE will act as a reminder to drug developers excited by potential breakthroughs that health technology assessment has become an exacting filter for new medicines to pass through.
Daiichi’s EZH Contender Moves Ahead In Leukemia/Lymphoma
Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.